WO2003035868A1 - Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels - Google Patents
Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels Download PDFInfo
- Publication number
- WO2003035868A1 WO2003035868A1 PCT/EP2002/011968 EP0211968W WO03035868A1 WO 2003035868 A1 WO2003035868 A1 WO 2003035868A1 EP 0211968 W EP0211968 W EP 0211968W WO 03035868 A1 WO03035868 A1 WO 03035868A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strand
- dsrna
- sequence seq
- nucleotides
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Definitions
- the invention relates to a medicament and a use for increasing the effectiveness of a receptor-mediated apoptosis in a drug that triggers tumor cells.
- the invention further relates to a use for the production of such a medicament, a method for increasing the effectiveness of a receptor-mediated apoptosis in an active substance which triggers tumor cells, and a double-stranded ribonucleic acid.
- DE 101 00 586 C1 discloses a method for inhibiting the expression of a target gene in a cell, in which an oligoribonucleotide with a double-stranded structure is introduced into the cell.
- One strand of the double-stranded structure is complementary to the target gene.
- the principle on which inhibition is based is now known as RNA interference.
- a well-known active ingredient that triggers apoptosis is the tumor
- TRAIL activates a caspase by binding to TRAIL-Rl and TRAIL-R2, two members of the TNF receptor superfamily that contain a death domain, and thereby triggers apoptosis in tumor cells.
- mice embryonic fibroblasts which lack the cellular F ICE inhibitor protein (c-FLIP) are particularly sensitive to receptor-mediated apoptosis. However, these cells were not tumor cells.
- c-FLIP cellular F ICE inhibitor protein
- splice variants of c-FLIP are known, including a short splice variant c-FLIP-S and a long splice variant c-FLIP-L. From Bin, L. et al. , FEBS Lett 510 (1-2) (2002), pages 37 to 40, it is known that c-FLIP-deficient embryonic mouse fibroblasts become resistant to TRAIL-induced apoptosis by retrovirally mediated transduction of c-FLIP-S.
- Tumor cells are often not or hardly sensitive to drugs or active substances that trigger apoptosis. Treatment with such drugs therefore often requires co-treatment by radiation or chemotherapy in order to achieve a therapeutic effect of the drug which triggers apoptosis.
- the co-treatments mentioned are accompanied by strong side effects.
- the object of the present invention is to eliminate the disadvantages of the prior art.
- a medicament, a double-stranded ribonucleic acid and a use for increasing the effectiveness of an apoptosis in tumor cell-inducing medicament are to be provided, which avoids the strong side effects mentioned above.
- a use for the production of such a medicament and a method for increasing the effectiveness of an apoptosis in an agent which triggers tumor cells are to be provided.
- a medicament is provided to increase the effectiveness of a receptor-mediated apoptosis in drug which triggers tumor cells, the medicament containing a double-stranded ribonucleic acid (dsRNA) which is suitable for inhibiting the expression of a c-FLIP gene by means of RNA interference.
- dsRNA double-stranded ribonucleic acid
- a dsRNA is present if it consists of a or two ribonucleic acid strands consisting of ribonucleic acid has a double-stranded structure. Not all nucleotides of the dsRNA have to have canonical Watson-Crick base pairings. In particular, individual non-complementary base pairs have little or no effect on the effectiveness. The maximum possible number of base pairs is the number of nucleotides in the shortest strand contained in the dsRNA.
- the medicament can contain the dsRNA in an amount sufficient to inhibit the expression of the c-FLIP gene in the tumor cells.
- the drug can also be designed so that several units of the drug together contain the sufficient amount in total. The sufficient amount depends on the form of administration.
- the dsRNA can be administered in increasing amounts or doses. Then, using a tissue sample taken from the tumor, it can be determined using known methods whether the expression of the c-FLIP gene has been inhibited with this amount. The methods can e.g. are molecular biological, biochemical or immunological methods.
- RNA interference enables targeted treatment of tumors with few side effects or weak side effects, with drugs that specifically trigger the apoptosis of tumor cells.
- the drug preferably triggers apoptosis by means of tumor necrosis factor or tumor necrosis factor-related ligands which trigger apoptosis, in particular TRAIL.
- the effective speed of such a drug can be increased particularly effectively by the method according to the invention.
- a strand S1 of the dsRNA preferably has a region which is complementary to the c-FLIP gene, at least in sections, and in particular comprises fewer than 25 successive nucleotides.
- the “c-FLIP gene” is understood to mean the DNA strand of the double-stranded DNA coding for c-FLIP in the tumor cell, which is complementary to a DNA strand which serves as a template during transcription, including all transcribed areas.
- the c-FLIP gene is therefore generally the sense strand.
- the strand S1 can thus be complementary to an RNA transcript formed during the expression of the c-FLIP gene or its processing product, such as e.g. an mRNA. For example, be sufficient if the strand S1 is complementary to part of the 3 'untranslated region of the mRNA.
- the complementary region of the dsRNA can have 19 to 24, preferably 20 to 24, particularly preferably 21 to 23, in particular 22 or 23, nucleotides.
- a dsRNA with this structure is particularly efficient in inhibiting the c-FLIP gene.
- the strand S1 of the dsRNA can have less than 30, preferably less than 25, particularly preferably 21 to 24, in particular 23, nucleotides. The number of these nucleotides is also the number of the maximum possible base pairs in the dsRNA.
- dsRNA has a single-stranded overhang formed from 1 to 4, in particular 2 or 3, nucleotides.
- a dsRNA has a better effectiveness in inhibiting the expression of the c-FLIP gene than at least one end of a dsRNA without single-stranded overhangs.
- One end is a region of the dsRNA in which there is a 5 'and a 3' strand end.
- One only dsRNA existing in strand S1 accordingly has a loop structure and only one end.
- a dsRNA formed from the strand S1 and a strand S2 has two ends. One end is formed in each case by one end of strand S1 and one end of strand S2.
- the single-stranded overhang is preferably located at the 3 'end of the strand S1. This localization of the single-stranded overhang leads to a further increase in the efficiency of the drug.
- the dsRNA can also have a single-stranded overhang only at one end, in particular at the end located at the 3 'end of the strand S1. The other end is smooth on a double ended dsRNA, i.e. without overhangs, trained. Surprisingly, it has been shown that an overhang at one end of the dsRNA is sufficient to enhance the interference effect of the dsRNA, without lowering the stability to the same extent as by two overhangs.
- a dsRNA with only one overhang has proven to be sufficiently stable and particularly effective both in various cell culture media and in blood, serum and cells.
- the dsRNA preferably has a strand S2, ie it is formed from two individual strands.
- the medicament is particularly effective if the strand S1 (anti-sense strand) has a length of 23 nucleotides, the strand S2 has a length of 21 nucleotides and the 3 'end of the strand S1 has a single-stranded overhang formed from two nucleotides , The end of the dsRNA located at the 5 'end of the strand S1 is smooth.
- the strand S1 can be complementary to the primary or processed RNA transcript of the c-FLIP gene.
- the dsRNA preferably consists of strand S2 with the sequence SEQ ID NO: 1 and strand S1 with the sequence SEQ ID NO: 2 or strand S2 with the sequence SEQ ID NO: 3 and strand S1 with the sequence SEQ ID NO : 4 or the strand S2 with the sequence SEQ ID NO: 1 and the strand S1 with the sequence SEQ ID NO: 7 or the strand S2 with the sequence SEQ ID NO: 3 and the strand S1 with the sequence SEQ ID NO: 8 according to the attached sequence listing.
- a dsRNA is particularly effective in inhibiting the expression of the c-FLIP gene.
- the dsRNA can be enclosed in the medicament in a solution, in particular a physiologically compatible buffer or a physiological saline solution, of a micellar structure, preferably a liposome, a capsid, a capsoid or a polymeric nano- or microcapsule, or on a polymeric nanocapsule. or microcapsule bound.
- the physiologically compatible buffer can be a phosphate-buffered saline solution.
- a micellar structure, a capsid, a capsoid or a polymeric nano or microcapsule can facilitate the uptake of the dsRNA into the tumor cells.
- the polymeric nano or microcapsule consists of at least one biodegradable polymer, e.g. Polybutylcyanoacry- lat.
- the polymeric nano- or microcapsule can transport and release dsRNA contained in or bound to it in the body.
- the dsRNA can be administered orally, by inhalation, infusion or injection, in particular intravenous, intraperitoneal or intratumoral infusion or injection.
- the medicament can therefore have a preparation which is suitable for inhalation, oral ingestion, infusion or injection, in particular for intravenous, intraperitoneal or intratumoral infusion or injection.
- a preparation suitable for inhalation, infusion or injection can consist of a physiologically compatible solvent, preferably a physiological saline solution or a physiologically compatible buffer, in particular a phosphate-buffered salt solution, and the dsRNA.
- a dsRNA which is only dissolved and administered in such a buffer or solvent is taken up by the tumor cells and inhibits the expression of the c-FLIP gene without the dsRNA having to be packaged in a special vehicle.
- the medicament is preferably present in at least one administration unit which contains the dsRNA in an amount which has a dosage of at most 5 mg, in particular at most 2.5 mg, preferably at most 200 ⁇ g, particularly preferably at most 100 ⁇ g, preferably at most 50 ⁇ g, in particular allows a maximum of 25 ⁇ g per kg body weight and day. It has been shown that the dsRNA has an excellent effectiveness in inhibiting the expression of the c-FLIP gene even at this dosage.
- the administration unit can be designed for a single administration or intake per day. Then the entire daily dose is contained in one administration unit. If the administration unit is designed for repeated administration or ingestion per day, the dsRNA is contained therein in a correspondingly smaller amount that enables the daily dose to be reached.
- the administration unit can also be designed for a single administration or ingestion for several days, e.g. B. by releasing the dsRNA over several days. The administration unit then contains a corresponding multiple of the daily dose.
- the use of a double-stranded ribonucleic acid suitable for inhibiting the expression of a c-FLIP gene by means of RNA interference is furthermore provided for the manufacture of a medicament for increasing the effectiveness of a receptor-mediated drug which triggers apoptosis in tumor cells.
- the invention furthermore relates to the use of a double-stranded ribonucleic acid which is suitable for inhibiting the expression of a c-FLIP gene by means of RNA interference intended to increase the effectiveness of a receptor-mediated apoptosis in drug-inducing drug.
- a method for increasing the effectiveness of a receptor-mediated apoptosis in an active agent which triggers a tumor cell, a double-stranded ribonucleic acid suitable for inhibiting the expression of a c-FLIP gene by means of RNA interference being introduced into the tumor cell.
- "To be introduced” is understood to mean the absorption into the cell. It can be picked up by the cell itself. However, it can also be imparted by means of auxiliary substances or aids.
- the invention also relates to a double-stranded ribonucleic acid, one strand S1 of which has a region which is at least partially complementary to the c-FLIP gene.
- KB cells are from the American Type Culture Collection
- ATCC ATCC under the ATCC no. CCL-17 available.
- SV80 cells can be obtained from CLS, 69123 Heidelberg, Germany under order number 0345 HU (ATCC no .: CRL-7725).
- the dsRNAs used have the following sequences, designated SEQ ID NO: 1 to SEQ ID NO: 9 in the sequence listing:
- dsRNA-Fl which corresponds to nucleotides 472 to 492 of the c-flip-L gene:
- S2 5'-GUGCCGGGAUGUUGCUAUAGA-3 '(SEQ ID NO: 1)
- Sl 3' -AACACGGCCCUACAACGAUAU-5 '(SEQ ID NO: 2)
- dsRNA-F2 which corresponds to nucleotides 908 to 928 of the c-flip-L gene:
- S2 5'-CAAGGAGCAGGGACAAGUUAC-3 '(SEQ ID NO: 3)
- Sl 3' -AAGUUCCUCGUCCCUGUUCAA-5 '(SEQ ID NO: 4)
- dsRNA-neo which is complementary to a sequence from the neomycin resistance gene:
- S2 5 '-GAUGAGGAUCGUUUCGCAUGA-3' (SEQ ID NO: 5)
- Sl 3 '-UCCUACUCCUAGCAAAGCGUA-5' (SEQ ID NO: 6)
- dsRNA-F3 which corresponds to nucleotides 472 to 494 of the c-flip-L gene:
- S2 5 '-GUGCCGGGAUGUUGCUAUAGA-3' (SEQ ID NO: 1)
- Sl 3 '-AACACGGCCCUACAACGAUAUCU-5' (SEQ ID NO: 7)
- dsRNA-F4 which corresponds to nucleotides 908 to 930 of the c-flip-L gene:
- S2 5 '-CAAGGAGCAGGGACAAGUUAC-3' (SEQ ID NO: 3)
- Sl 3 '-AAGUUCCUCGUCCCUGUUCAAUG-5' (SEQ ID NO: 8) dsRNA control, which is complementary to a sequence from the neomycin resistance gene:
- S2 5 '-GAUGAGGAUCGUUUCGCAUGA-3' (SEQ ID NO: 5)
- Sl S'-UCCUACUCCUAGCAAAGCGUACU-S '(SEQ ID NO: 9)
- Each 10 7 SV80 and KB cells per ml are transiently electroplated twice on consecutive days without (FIG. 1A, FIG. 2A) or with 150 nmol / 1 dsRNA-neo (FIG. 1B, FIG. 2 B), 150 nmol / 1 dsRNA-Fl (Fig. 1 C, Fig. 2 C), 150 nmol / 1 dsRNA-F2 (Fig. 1 D, Fig. 2 D) or a mixture of 75 nmol / 1 each dsRNA-Fl and dsRNA-F2 (Fig. 1 E, Fig. 2 E) have been transfected.
- a GFP (green fluorescent protein) expression plasmid was added to the electroporation solution in order to be able to check the respective efficiency of the transfection.
- the cells were harvested one day after the first electroporation. With some of the cells, the transfection efficiency was determined by flow cytometry by measuring the fluorescence intensity. The fluorescence intensity of these cells is shown in FIGS. 1 AE and 2 AE in each case in the left field by a solid thick line. The fluorescence intensity represented by a thin line in the same field is that of the same cells without a GFP expression plasmid.
- the other part of the cells was electroporated a second time with the same dsRNA as on the first day. The cells were then seeded into the wells of 96-well plates in 100 ⁇ l medium. The next day the cells were incubated with for 9 h each
- TRAIL Flag-coupled soluble TRAIL
- TRAIL + ZVAD Flag-coupled soluble cross-linked TRAIL as indicated above in the presence of 20 ⁇ mol / 1 of the caspase inhibitor z-VAD-fmk
- dsRNA-Fl and dsRNA-F2 (FIG. 1 CE, FIG. 2 CE), but not dsRNA-neo (FIG. 1 B, FIG. 2 B) or electroporation without dsRNA (mock electroporation) (FIG. 1 A, FIG. 2A) have significantly sensitized KB and SV80 cells for TRAIL-Rl and TRAIL-R2 mediated apoptosis.
- ZVAD has raised awareness of TRAIL-induced apoptosis. This indicates the involvement of caspases (Fig. 1 C-E, Fig. 2 C-E).
- KB cells were also sensitized to FasL and TNF-induced apoptosis by treatment with dsRNA-Fl and dsRNA-F2.
- the overhangs are each formed by the 3 'ends of the strands S1 and S2.
- the double-stranded region has a length of 19 nucleotide pairs. Additional experiments to inhibit FLIP-mRNA expression were carried out with the dsRNAs dsRNA-F3, dsRNA-F4 and dsRNA control performed. In these, only one end of the dsRNA has an overhang formed from two nucleotides at the 3 'end of the S1 strand.
- the double-stranded region is 21 nucleotides in length.
- a quantitative analysis has shown that dsRNA-F3 and dsRNA-F4 are about as effective in inhibiting the expression of a GFP-flip fusion protein as dsRNA-Fl and dsRNA-F2.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10230996A DE10230996A1 (de) | 2001-10-26 | 2002-07-09 | Medikament zur Behandlung eines Pankreaskarzinoms |
DE10230997A DE10230997A1 (de) | 2001-10-26 | 2002-07-09 | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
JP2003538370A JP2005506385A (ja) | 2001-10-26 | 2002-10-25 | 膵臓癌を処置するための医薬 |
PCT/EP2002/011971 WO2003035082A1 (de) | 2001-10-26 | 2002-10-25 | Medikament zur hemmung der expression eines zielgens |
US10/382,634 US20040038921A1 (en) | 2001-10-26 | 2003-08-11 | Composition and method for inhibiting expression of a target gene |
US10/666,458 US20040126791A1 (en) | 2001-10-26 | 2003-09-19 | Compositions and methods for treating trail-resistant cancer cells |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10155280.7 | 2001-10-26 | ||
DE10155280 | 2001-10-26 | ||
DE10158411.3 | 2001-11-29 | ||
DE10158411 | 2001-11-29 | ||
DE10160151.4 | 2001-12-07 | ||
DE10160151A DE10160151A1 (de) | 2001-01-09 | 2001-12-07 | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
EPPCT/EP02/00152 | 2002-01-09 | ||
PCT/EP2002/000152 WO2002055693A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens |
PCT/EP2002/000151 WO2002055692A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung |
EPPCT/EP02/00151 | 2002-01-09 | ||
DE10230997A DE10230997A1 (de) | 2001-10-26 | 2002-07-09 | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
DE10230997.3 | 2002-07-09 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/666,458 Continuation-In-Part US20040126791A1 (en) | 2001-10-26 | 2003-09-19 | Compositions and methods for treating trail-resistant cancer cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003035868A1 true WO2003035868A1 (de) | 2003-05-01 |
Family
ID=39189390
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/011972 WO2003035083A1 (de) | 2001-10-26 | 2002-10-25 | Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz |
PCT/EP2002/011968 WO2003035868A1 (de) | 2001-10-26 | 2002-10-25 | Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/011972 WO2003035083A1 (de) | 2001-10-26 | 2002-10-25 | Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080070856A1 (de) |
JP (1) | JP2005512976A (de) |
CN (1) | CN1604783A (de) |
WO (2) | WO2003035083A1 (de) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1486564A1 (de) * | 2003-06-13 | 2004-12-15 | Ribopharma AG | SiRNA mit erhöhter Stabilität in Serum |
WO2005053725A2 (en) * | 2003-11-26 | 2005-06-16 | The Queen's University Of Belfast | Cancer treatment |
EP1633770A2 (de) * | 2003-06-13 | 2006-03-15 | Alnylam Europe AG | Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus |
US7196184B2 (en) | 2002-01-22 | 2007-03-27 | Alnylam Europe Ag | Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene |
US7348314B2 (en) | 2001-10-12 | 2008-03-25 | Alnylam Europe Ag | Compositions and methods for inhibiting viral replication |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7473525B2 (en) | 2001-01-09 | 2009-01-06 | Alnylam Europe Ag | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
EP2292739A1 (de) | 2006-03-24 | 2011-03-09 | Institut National De La Recherche Agronomique | Verfahrung zur Herstellung differenzierter Zellen vom Huhn, und Gene, die im Erhalt der Pluripotenz impliziert sind |
US8101742B2 (en) | 1999-01-30 | 2012-01-24 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US9074213B2 (en) | 2001-01-09 | 2015-07-07 | Alnylam Pharmacuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
EP3492107A4 (de) * | 2016-07-29 | 2020-03-11 | Abion Inc. | Zusammensetzung zur behandlung oder sensibilisierung von interferon-beta-resistenter krebserkrankung mit cflip-sirna |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070004657A1 (en) * | 2003-11-17 | 2007-01-04 | Orna Mor | Diagnosis and treatment of kidney fibrosis and other fibrotic diseases |
JP4543189B2 (ja) * | 2004-03-10 | 2010-09-15 | 学校法人日本医科大学 | TGFβ1レセプターII型に対するRNAiとして作用するRNA配列 |
WO2010021720A1 (en) * | 2008-08-19 | 2010-02-25 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
CN107083386A (zh) * | 2008-08-25 | 2017-08-22 | 埃克斯雷德制药有限公司 | 阻止***生长因子的反义核苷酸及其用途 |
US8946172B2 (en) * | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
EP3336188B1 (de) * | 2008-09-22 | 2020-05-06 | Phio Pharmaceuticals Corp. | Selbstfreisetzende rnai-verbindungen von reduzierter grösse |
CN102666587A (zh) | 2009-07-02 | 2012-09-12 | 菲布罗根有限公司 | 用于治疗肌营养不良的方法 |
WO2011035065A1 (en) | 2009-09-17 | 2011-03-24 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
US20120244169A1 (en) | 2009-11-06 | 2012-09-27 | Fibrogen, Inc. | Treatment for Radiation-Induced Disorders |
EP2550001B1 (de) | 2010-03-24 | 2019-05-22 | Phio Pharmaceuticals Corp. | Rna-interferenz bei augenerkrankungen |
WO2011119887A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
JP6081910B2 (ja) | 2010-06-02 | 2017-02-15 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 肝線維症治療用組成物および肝線維症の治療法 |
AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
WO2012061811A2 (en) | 2010-11-05 | 2012-05-10 | Fibrogen, Inc. | Treatment method for lung remodeling diseases |
US9173894B2 (en) | 2011-02-02 | 2015-11-03 | Excaliard Pharamaceuticals, Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF) |
JP6726105B2 (ja) | 2014-12-15 | 2020-07-22 | 株式会社ボナック | TGF−β1発現抑制のための一本鎖核酸分子 |
EP3386544B1 (de) | 2015-12-10 | 2020-11-25 | Fibrogen, Inc. | Verfahren zur behandlung von motoneuronenerkrankungen |
CN109432047B (zh) * | 2018-10-29 | 2021-07-20 | 中国药科大学 | 一种逆转肺纤维化纳米制剂及其制备方法 |
US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
CN112843253B (zh) * | 2021-01-13 | 2023-07-14 | 上海交通大学 | 一种基因/药物复合脂质制剂及其制备方法和用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998005770A2 (de) * | 1996-08-07 | 1998-02-12 | Deutches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts | Anti-sinn-rna mit sekundärstruktur |
WO1998033883A1 (en) * | 1997-02-05 | 1998-08-06 | Tularik, Inc. | Regulators of apoptosis |
WO1998044104A2 (de) * | 1997-04-01 | 1998-10-08 | Apotech Research And Development Ltd. | Flip-gen und flip-protein |
WO2000044895A1 (de) * | 1999-01-30 | 2000-08-03 | Roland Kreutzer | Verfahren und medikament zur hemmung der expression eines vorgegebenen gens |
WO2001075164A2 (en) * | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
WO2002044321A2 (en) * | 2000-12-01 | 2002-06-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6984594A (en) * | 1993-06-15 | 1995-01-17 | Hun Taeg Chung | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AU4411499A (en) * | 1998-06-05 | 1999-12-20 | Human Genome Sciences, Inc. | Connective tissue growth factor-4 |
US6844319B1 (en) * | 1998-10-08 | 2005-01-18 | Stichting Voor De Technische Wetenschappen | Peptide-based carrier devices for stellate cells |
WO2000027868A2 (en) * | 1998-11-06 | 2000-05-18 | Fibrogen, Inc. | Connective tissue growth factor (ctgf) and methods of use |
AU773278B2 (en) * | 1998-12-14 | 2004-05-20 | University Of Miami | Connective tissue growth factor fragments and methods and uses thereof |
CA2381006A1 (en) * | 1999-09-17 | 2001-03-22 | Nicholas M. Dean | Antisense modulation of transforming growth factor-.beta. expression |
GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
-
2002
- 2002-10-25 JP JP2003537650A patent/JP2005512976A/ja active Pending
- 2002-10-25 CN CNA028251636A patent/CN1604783A/zh active Pending
- 2002-10-25 WO PCT/EP2002/011972 patent/WO2003035083A1/de active Application Filing
- 2002-10-25 WO PCT/EP2002/011968 patent/WO2003035868A1/de not_active Application Discontinuation
-
2007
- 2007-05-11 US US11/747,549 patent/US20080070856A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998005770A2 (de) * | 1996-08-07 | 1998-02-12 | Deutches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts | Anti-sinn-rna mit sekundärstruktur |
WO1998033883A1 (en) * | 1997-02-05 | 1998-08-06 | Tularik, Inc. | Regulators of apoptosis |
WO1998044104A2 (de) * | 1997-04-01 | 1998-10-08 | Apotech Research And Development Ltd. | Flip-gen und flip-protein |
WO2000044895A1 (de) * | 1999-01-30 | 2000-08-03 | Roland Kreutzer | Verfahren und medikament zur hemmung der expression eines vorgegebenen gens |
WO2001075164A2 (en) * | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
WO2002044321A2 (en) * | 2000-12-01 | 2002-06-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
Non-Patent Citations (7)
Title |
---|
AMBROS VICTOR: "Dicing up RNAs", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 293, no. 5531, 3 August 2001 (2001-08-03), pages 811 - 813, XP002183122, ISSN: 0036-8075 * |
BASS BRENDA L: "Double-stranded RNA as a template for gene silencing", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 101, no. 3, 28 April 2000 (2000-04-28), pages 235 - 238, XP002194756, ISSN: 0092-8674 * |
BIN A L ET AL: "The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 510, no. 1-2, 2 January 2002 (2002-01-02), pages 37 - 40, XP004330501, ISSN: 0014-5793 * |
GRIFFITH T. S.,CHIN W. A. ET AL.: "Intracellular regulation of trail-induced apoptosis in human melanoma cells.", J. IMMUNOL., vol. 161, 1998, pages 2833 - 2840, XP002230470 * |
SIEGMUND D. ET AL.: "Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis.", MOLECULAR MEDICINE, vol. 8, no. 11, November 2002 (2002-11-01), pages 725 - 732, XP009005569 * |
ZAMORE PHILLIP D ET AL: "RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 101, no. 1, 31 March 2000 (2000-03-31), pages 25 - 33, XP002208683, ISSN: 0092-8674 * |
ZHANG X.D., FRANCO A. ET AL.: "Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.", CANCER RES., vol. 59, 1 June 1999 (1999-06-01), pages 2747 - 2753, XP002230469 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9902955B2 (en) | 1999-01-30 | 2018-02-27 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US9133454B2 (en) | 1999-01-30 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8729037B2 (en) | 1999-01-30 | 2014-05-20 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8202980B2 (en) | 1999-01-30 | 2012-06-19 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8183362B2 (en) | 1999-01-30 | 2012-05-22 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8168776B2 (en) | 1999-01-30 | 2012-05-01 | Alnylam Pharmaceuticals, Inc. | Method for making a 21 nucleotide double stranded RNA chemically linked at one end |
US8119608B2 (en) | 1999-01-30 | 2012-02-21 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8114851B2 (en) | 1999-01-30 | 2012-02-14 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8114981B2 (en) | 1999-01-30 | 2012-02-14 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8101584B2 (en) | 1999-01-30 | 2012-01-24 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US8101742B2 (en) | 1999-01-30 | 2012-01-24 | Alnylam Pharmaceuticals, Inc. | Method and medicament for inhibiting the expression of a given gene |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7473525B2 (en) | 2001-01-09 | 2009-01-06 | Alnylam Europe Ag | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US9587240B2 (en) | 2001-01-09 | 2017-03-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7868160B2 (en) | 2001-01-09 | 2011-01-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US9074213B2 (en) | 2001-01-09 | 2015-07-07 | Alnylam Pharmacuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7763590B2 (en) | 2001-10-12 | 2010-07-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a mutant gene |
US7348314B2 (en) | 2001-10-12 | 2008-03-25 | Alnylam Europe Ag | Compositions and methods for inhibiting viral replication |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
US7846907B2 (en) | 2002-01-22 | 2010-12-07 | Alnylam Pharmaceuticals, Inc. | Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene |
US7196184B2 (en) | 2002-01-22 | 2007-03-27 | Alnylam Europe Ag | Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene |
EP1633770A4 (de) * | 2003-06-13 | 2008-04-16 | Alnylam Europe Ag | Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus |
US7786290B2 (en) | 2003-06-13 | 2010-08-31 | Alnylam Pharmaceuticals, Inc. | Double-stranded ribonucleic acid with increased effectiveness in an organism |
EP1633770A2 (de) * | 2003-06-13 | 2006-03-15 | Alnylam Europe AG | Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus |
EP1486564A1 (de) * | 2003-06-13 | 2004-12-15 | Ribopharma AG | SiRNA mit erhöhter Stabilität in Serum |
WO2005053725A3 (en) * | 2003-11-26 | 2005-12-08 | Univ Belfast | Cancer treatment |
WO2005053725A2 (en) * | 2003-11-26 | 2005-06-16 | The Queen's University Of Belfast | Cancer treatment |
EP2292739A1 (de) | 2006-03-24 | 2011-03-09 | Institut National De La Recherche Agronomique | Verfahrung zur Herstellung differenzierter Zellen vom Huhn, und Gene, die im Erhalt der Pluripotenz impliziert sind |
EP3492107A4 (de) * | 2016-07-29 | 2020-03-11 | Abion Inc. | Zusammensetzung zur behandlung oder sensibilisierung von interferon-beta-resistenter krebserkrankung mit cflip-sirna |
EP4012030A1 (de) * | 2016-07-29 | 2022-06-15 | Abion Inc. | Zusammensetzung zur behandlung oder sensibilisierung von interferon-beta-resistenter krebserkrankung mit cflip-sirna |
KR102666000B1 (ko) | 2016-07-29 | 2024-05-14 | 서울대학교 산학협력단 | cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
JP2005512976A (ja) | 2005-05-12 |
WO2003035083A1 (de) | 2003-05-01 |
CN1604783A (zh) | 2005-04-06 |
US20080070856A1 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003035868A1 (de) | Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels | |
DE10230997A1 (de) | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels | |
EP1349927B1 (de) | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung | |
DE60037938T2 (de) | Antisense-therapie für trpm-2 | |
DE69835761T2 (de) | Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel | |
EP1352061B1 (de) | Verfahren zur hemmung der expression eine zielgens | |
WO2003035869A1 (de) | Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens | |
DE10202419A1 (de) | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens | |
WO2003035870A1 (de) | Medikament zur behandlung eines pankreaskarzinoms | |
DE10100587C1 (de) | Verfahren zur Hemmung der Expression eines Zielgens | |
DE10049549A1 (de) | Modulation der Transkription pro-inflammatorischer Genprodukte | |
WO2003035082A1 (de) | Medikament zur hemmung der expression eines zielgens | |
EP0655926A1 (de) | Neue sonde zur tumordiagnostik oder tumortherapie | |
EP2289520A1 (de) | Verwendung von Acetylsalicylsäure zur Prophylaxe und/oder Therapie von Influenzavirus Infekten. | |
DE69534197T2 (de) | Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält | |
DE69432444T2 (de) | Promotor-Sequenz des Rezeptors p55 für Tumor-Nekrosis-Faktor | |
DE102007031574B4 (de) | Minor-Spleißosom Testsystem zur Modulierung der Zellteilung | |
DE69533804T2 (de) | Mimetika von aus alternden Zellen abgeleiteten Hemmern der DNA-Synthese | |
EP3586132B1 (de) | Medikament zur malignombehandlung | |
DE69936632T2 (de) | Hemmung der cytokin-herstellung | |
Muinos-Buehl | Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA) | |
EP1536840B1 (de) | Formulierung zur einschleusung von nukleinsäuren in eukaryotischen zellen | |
EP1080192B1 (de) | Antisense-oligonukleotide zur behandlung von proliferierenden zellen | |
Zander | Characterization of cell-intrinsic antiviral response pathways in the context of DNA damage-induced cell death | |
EP2264173A2 (de) | Verwendung einer doppelsträngigen Ribonukleinsäure zur gezielten Hemmung der Expression eines vorgegebenen Zielgens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10666458 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |